Related Experiment Video
Updated: Jun 20, 2026
09:49
Isolation of Region-specific Microglia from One Adult Mouse Brain Hemisphere for Deep Single-cell RNA Sequencing
Published on: December 3, 2019
10.7K
Decoding Alzheimer's Disease: Single-Cell Sequencing Uncovers Brain Cell Heterogeneity and Pathogenesis
Ya-Nan Ma1, Ying Xia1,2, Kenji Karako3
1Department of Neurosurgery, Haikou Affiliated Hospital of Central South University Xiangya School of Medicine, Haikou, 570208, China.
Molecular Neurobiology
|April 30, 2025
Summary
Single-cell sequencing reveals cell-specific changes in Alzheimer's disease (AD) brains. These findings illuminate AD pathogenesis and identify new targets for precision medicine.
Area of Science:
- Neuroscience
- Genomics
- Molecular Biology
Background:
- Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by cognitive decline and neuropathology.
- Single-cell sequencing technologies offer high-resolution insights into the cellular and molecular landscape of the AD brain.
Purpose of the Study:
- To systematically review the application of single-cell transcriptomic and epigenomic approaches in Alzheimer's disease research.
- To characterize cell type- and subtype-specific transcriptomic alterations in AD.
- To explore the potential for identifying novel therapeutic targets and biomarkers.
Main Methods:
- Review of single-cell RNA sequencing (scRNA-seq) studies in AD.
- Analysis of assays for transposase-accessible chromatin using sequencing (ATAC-seq) data in AD.
- Integration of spatial transcriptomics to understand cellular communication networks.
Main Results:
- Identification of selectively vulnerable neuronal and glial subpopulations in AD.
- Characterization of transcriptional dysregulation linked to AD genetic risk loci (e.g., APOE, TREM2).
- Elucidation of disease trajectories and cellular communication networks across pathological stages.
Conclusions:
- Single-cell approaches significantly enhance the understanding of Alzheimer's disease pathogenesis.
- These insights pave the way for precision medicine strategies in AD treatment.
- Novel therapeutic targets and biomarkers can be identified through advanced single-cell analyses.
Related Concept Videos
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...